NBI-1065890

· Neurocrine Biosciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NBI-1065890, covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia [Phase 2]